Department of Phytochemistry, Centre for Plant Medicine Research, Mampong-Akwapim, Ghana.
Department of Phytochemistry, Centre for Plant Medicine Research, Mampong-Akwapim, Ghana.
J Ethnopharmacol. 2021 Feb 10;266:113427. doi: 10.1016/j.jep.2020.113427. Epub 2020 Oct 3.
Malaria is caused by infection with some species of Plasmodium parasite which leads to adverse alterations in physical and hematological features of infected persons and ultimately results in death. Antrocaryon micraster is used to treat malaria in Ghanaian traditional medicine. However, there is no scientific validation of its anti-malaria properties. The plant does not also have any chemical fingerprint or standardization parameters.
This study sought to evaluate the anti-malaria activity of standardized A. micraster stem bark extract (AMSBE) and its effect on mean survival time (MST) and body weight reduction of Plasmodiumberghei infested mice. And to study the effect of treatment of AMSBE on hematological indices of the P. berghei infested mice in order to partly elucidate its anti-malarial mechanism of action.
Malaria was induced in female ICR mice by infecting them with 0.2 mL of blood (i.p.) containing 1.0 × 10P. berghei-infested RBCs from a donor mouse and leaving them without treatment for 3 days. AMSBE or Lonart (standard control) was then orally administered at 50, 200 and 400 mg/kg or 10 mg/kg once daily for 4 consecutive days. The untreated control received sterile water. Malaria parasitemia reduction, anti-malarial activity, mean change in body weight and MST of the parasitized mice were evaluated. Furthermore, changes in white blood cells (WBCs), red blood cells (RBCs), platelets count, hemoglobin (HGB), hematocrit (HCT) and mean corpuscular volume (MCV) were also determined in the healthy animals before infection as baseline and on days 3, 5 and 8 after infection by employing complete blood count. Standardization of AMSBE was achieved by quantification of its constituents and chemical fingerprint analysis using UHPLC-MS.
Administration of AMSBE, standardized to 41.51% saponins and 234.960 ± 0.026 mg/g of GAE phenolics, produced significant (P < 0.05) reduction of parasitemia development, maximum anti-malaria activity of 46.01% (comparable to 32.53% produced by Lonart) and significantly (P < 0.05) increased body weight and MST of P. berghei infected mice compared to the untreated control. Moreover, there were significant (P > 0.05) elevation in WBCs, RBCs, HGB, HCT and platelets in the parasitized-AMSBE (especially at 400 mg/kg p.o.) treated mice compared to their baseline values. Whereas, the non-treated parasitized control recorded significant reduction (P < 0.05) in all the above-mentioned parameters compared to its baseline values. The UHPLC-MS fingerprint of AMSBE revealed four compounds with their retention times, percentage composition in their chromatograms and m/z of the molecular ions and fragments in the spectra.
These results show that A. micraster stem bark possessed significant anti-malaria effect and also has the ability to abolish body weight loss, leucopenia, anemia and thrombocytopenia in P. berghei infected mice leading to prolonged life span. The UHPLC-MS fingerprint developed for AMSBE can be used for rapid authentication and standardization of A. micraster specimens and herbal preparations produced from its hydroethanolic stem bark extract to ensure consistent biological activity. The results justify A. micraster's use as anti-malaria agent.
疟疾是由某些疟原虫寄生虫感染引起的,导致感染者的身体和血液特征发生不良变化,最终导致死亡。安托卡里翁·米克拉斯特(Antrocaryon micraster)在加纳传统医学中用于治疗疟疾。然而,其抗疟特性尚未得到科学验证。该植物也没有任何化学指纹图谱或标准化参数。
本研究旨在评估标准化安托卡里翁·米克拉斯特茎皮提取物(AMSBE)的抗疟活性及其对感染伯氏疟原虫的小鼠平均存活时间(MST)和体重减轻的影响。并研究 AMSBE 对感染伯氏疟原虫的小鼠血液学指标的影响,以部分阐明其抗疟作用机制。
通过向雌性 ICR 小鼠腹腔内注射含有 1.0×10 个感染伯氏疟原虫 RBC 的 0.2mL 血液(i.p.)来诱导疟疾,让它们在没有治疗的情况下存活 3 天。然后,以 50、200 和 400mg/kg 或 10mg/kg 的剂量每天口服 AMSBE 或 Lonart(标准对照)一次,连续 4 天。未治疗的对照组给予无菌水。评估 AMSBE 对疟原虫减少、抗疟活性、感染小鼠体重变化和 MST 的影响。此外,还在感染前(作为基线)和感染后第 3、5 和 8 天,通过全血细胞计数确定健康动物的白细胞(WBC)、红细胞(RBC)、血小板计数、血红蛋白(HGB)、血细胞比容(HCT)和平均红细胞体积(MCV)的变化。通过 UHPLC-MS 对 AMSBE 进行定量和化学指纹图谱分析,实现其标准化。
给予 AMSBE(标准化至 41.51%皂苷和 234.960±0.026mg/g 的总酚酸)可显著(P<0.05)减少疟原虫发育,最大抗疟活性为 46.01%(与 Lonart 产生的 32.53%相当),并显著(P<0.05)增加感染伯氏疟原虫的小鼠体重和 MST。此外,与基线值相比,在接受 AMSBE 治疗的感染小鼠中,WBC、RBC、HGB、HCT 和血小板计数均显著升高(P>0.05)。而未经治疗的感染对照组与基线值相比,所有上述参数均显著降低(P<0.05)。AMSBE 的 UHPLC-MS 指纹图谱显示了四个化合物,其保留时间、色谱图中的百分比组成以及分子离子和谱图碎片的 m/z。
这些结果表明,安托卡里翁·米克拉斯特树皮具有显著的抗疟作用,还具有消除感染伯氏疟原虫小鼠体重减轻、白细胞减少、贫血和血小板减少的能力,从而延长其寿命。为 AMSBE 开发的 UHPLC-MS 指纹图谱可用于快速鉴定和标准化安托卡里翁·米克拉斯特标本及其从其水醇提树皮提取物中制备的草药制剂,以确保一致的生物活性。这些结果证明了安托卡里翁·米克拉斯特作为抗疟药物的用途。